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Abstract
This paper questions the implications of entrepreneurial responses to conditions of employment 
precarity by ‘healthy volunteers’ in phase I clinical trials in the United States. Such individuals are 
typically serial participants who often identify as professional volunteers and seek out drug studies 
as their primary source of income. Drawing on extensive qualitative research, this paper illustrates 
how healthy volunteers selectively import the identity of ‘hustler’ from the street environment and 
reposition it as connoting a set of valuable creative skills that give them a competitive edge over 
other participants. An entrepreneurial ethos allows them to view personal sacrifice and exposure to 
potentially dangerous drugs as smart investments leading to financially stable futures. These 
discursive moves normalize extractive, and at times dehumanizing, labour relations that offload 
expenses and risks to workers.
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Introduction
This paper explores the creative adaptations and entrepreneurial schemes of individuals 
participating in phase I clinical trials in the United States. Individuals working in this sector 
as ‘healthy volunteers’ effectively sell access to their bodies for testing the safety and side 
effects of experimental drugs. These participants are contract labourers, many of whom 
travel great distances in the hope of screening for and being included in studies, which 
typically pay anywhere from $25 for a screening visit to $10,000 for a lengthy study (Fisher, 
2015b). In some exceptional cases, individuals can earn around $17,000 for onerous studies 
lasting over three months (Madrigal, 2008).1 If individuals are selected, they are usually 
confined to a clinic for the duration of the study (ordinarily lasting a few days to a few 
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weeks), subjected to drug dosing and laboratory tests on a structured schedule, required to 
eat the dictated food and sleep when instructed and sometimes – out of intellectual property 
concerns on behalf of the sponsoring drug companies – relinquish their mobile phones and 
contacts with the outside world for the duration of their confinement (Motluck, 2009). The 
demands are clearly high on such workers, and they can also manifest extreme drug-induced 
side effects (e.g. cardiovascular irregularities, sleep paralysis with vivid nightmares, 
migraine headaches, incontinence, compromised immune systems, or death), in addition to 
being exposed to frequent and at times invasive or degrading tests (e.g. blood draws, lumbar 
punctures, stool collection) (Fisher, 2015a).
Healthy volunteers in the United States are primarily drawn from racial and ethnic minority 
groups, and most serial phase I participants are individuals who have a history of 
underemployment, with opportunities for income typically clustering in low-wage sectors 
(Fisher, 2015a; Fisher & Kalbaugh, 2011). Scholars have previously mobilized a trope of 
participants’ economic desperation driving them to enrol in clinical trials (Sunder Rajan, 
2007; VanderWalde & Kurzban, 2011), but this framing has the unfortunate tendency to 
erase healthy volunteers’ active and engaged decision-making about study participation. As 
we will illustrate, healthy volunteers in phase I clinical trials are anything but passive in the 
face of employment precarity. They assert agency and creativity in locating potential studies, 
travelling hundreds or thousands of miles to clinics, gaming screening processes to increase 
their chances for inclusion, disregarding mandatory ‘washout’ periods between studies and 
maintaining ‘healthy’ bodies during periods when they are not in studies. Additionally, these 
workers cultivate entrepreneurial identities both within and beyond the clinics. Many of 
them see their participation in clinical trials as a means to an end, serving as an investment 
to support their planned start-up companies, real-estate ventures or artistic endeavours. Some 
of the participants exploit the captive audience in clinics to network with and sell goods to 
others, effectively importing informal economic activities into the space of formal ones. An 
entrepreneurial culture flourishes in these confined, temporary communities and can be 
witnessed, for instance, when individuals criticize others for blowing their earnings on 
consumer goods instead of investing them in what they see as empowering business 
ventures.
In discussing the experiences of participants in phase I clinical trials, our aim is to question 
the implications of entrepreneurial responses to conditions of employment precarity. In other 
words, while it may be the case that casualization models of work have migrated up from 
low-wage employment sectors to cultural industries (Kalleberg, 2009; Ross, 2008), what are 
the effects of creative or entrepreneurial rationalities shaping the identities and practices of 
individuals working to survive on the margins? In what ways do such rationalities perform 
for those who do not feel that they have much choice, at present, about the work they do?
1Although these amounts may sound significant, based on preliminary data from our longitudinal study, most participants have a 
difficult time finding sufficient work in studies to stay above official poverty levels.
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Clinical trials as work
There has been increasing scholarly interest in clinical trials as work, primarily emerging 
from the fields of cultural anthropology and science and technology studies. This research 
parallels the rise of a massive clinical trials industry that is made up of diverse organizations 
that sell their services to pharmaceutical companies to aid in the testing of investigational 
drugs (Fisher, 2009). While the development of such an industry is in many respects a 
uniquely American phenomenon (Mirowski, 2011), many of these companies, especially so-
called contract research organizations (CROs), specialize in the global export of US models 
of clinical trials (Petryna, 2009). As a result, there has been an important expansion in 
pharmaceutical clinical trials being conducted both in the United States and Western Europe 
as well as in developing countries that have historically been resource-poor when it comes 
both to medical research and clinical care (Petryna et al., 2006). In spite of the increased 
diversity in clinical trial sites, the United States remains the primary site of pharmaceutical 
research worldwide for all stages of clinical trials from phase I through post-marketing 
studies (Lytle, 2012).
In addition to focusing on the researchers and organizations that conduct industry clinical 
trials, trial participants themselves are now central to empirical inquiry and conceptual 
analyses. Examining who participates in industry clinical trials allows for engagement not 
only with their experience of participating in clinical trials but also with how the decision to 
enrol in research is shaped by broader patterns of social and economic inequalities (Fisher, 
2013; Heimer, 2012; Joseph & Dohan, 2012; Kingori, 2013). For example, patients in the 
United States with inadequate access to health care might enrol in a clinical trial in order to 
have the opportunity to interact with health care providers and try an investigational drug 
that might ameliorate their medical condition (Fisher, 2007, 2009). The situation is even 
more dire in contexts with high mortality rates, pushing frontline workers to adhere to their 
own sense of ethics to help patients even when their actions are in conflict with the research 
protocols (Kingori, 2013).
With phase I clinical trials, it is primarily the economic context that dictates healthy 
individuals’ interest in enrolling in studies because they are typically motivated by the 
financial compensation they receive in exchange for their participation. This context can 
vary dramatically. For instance, Sunder Rajan (2007) found that one CRO in India opened its 
clinic location in the mill districts of Mumbai where unemployment had skyrocketed due to 
textile mill closures, taking advantage of the perfect conditions for finding research 
‘volunteers’. In contrast, Tolich (2010) found that most healthy volunteers in New Zealand 
were students who instead of seeking income for their very survival were participating in 
phase I studies as a way to afford ‘extras – a motorbike, a camera, a surfboard, a holiday to 
Nepal’ (Tolich, 2010, p. 767). The US context exhibits similarities to both of these ends of 
the economic spectrum with many healthy volunteers enrolling in studies as their primary 
source of income while others use it as supplemental income. What might be unique to US 
phase I trials, however, is the ‘professionalization’ of healthy volunteers who identify 
clinical trials as their work. Abadie (2010) describes a group of anarchist ‘professional 
guinea pigs’ who have made a career out of participating in clinical trials, in part for the 
flexibility that this form of work provides. Labour is so central to their view of clinical trials 
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that many of Abadie’s informants are union activists, advocating for so-called guinea pigs to 
organize as a means to demand better wages and work conditions.
Drawing in part upon the work of Abadie (2010) and Fisher (2015a) for empirical examples 
of clinical trial participants, Cooper and Waldby (2014) develop the concept of ‘clinical 
labour’ by situating tissue donors, surrogates and research participants in a deeply historical 
analysis of work and labour relations. Specifically, by theorizing clinical trial participation in 
this way, they make visible the material transactions that are critical to the production of 
knowledge, especially when science is a hugely profitable enterprise forming what can be 
thought of as the ‘bioeconomy’. Patients and healthy volunteers are both included as 
labourers in their assessment, with patients enrolled in a type of ‘workfare’ wherein the 
compensation for their trial participants is not in wages but in free diagnostic tests, drugs and 
medical oversight. Healthy volunteers are subjected to the same non-trial working conditions 
available to them, which can typically be characterized as casual, high-risk and precarious. 
In other words, whether in clinical trials or other employment sectors, work is never 
guaranteed and often tenuous.
With phase I participation, it is important to bear in mind that ‘healthy’ itself is an uncertain 
category because the ability to qualify for these clinical trials rests on meeting specific 
inclusion–exclusion criteria that are changeable depending on the needs of the 
pharmaceutical company. That is, the overall availability of clinical trials and the difficulty 
in assessing one’s exact biological state on any given day means that healthy volunteers 
cannot count on enrolling in a clinical trial whenever they choose to do so. We perceive 
these work conditions for healthy volunteers as similar to other precarious labour in that it 
encourages creative or entrepreneurial responses to those conditions while responsibilizing 
individuals for contending with their employment insecurity (Neff, 2012; de Peuter, 2011; 
Terranova, 2004). Just as an entrepreneurial ethos penetrates other sectors (Gill, 2007; 
Mumby, 2015; Roper & Cheney, 2005), it is taken up by healthy volunteers as an assertion 
of agency, allowing them to generate discourses of value and meaning for their participation 
in phase I trials. This may also, of course, further normalize exploitative conditions, but the 
phenomenon calls for empirical scrutiny to assess how individuals make sense of their own 
precarious relationship to the labour market.
Methods
This paper draws upon 178 semi-structured interviews conducted as part of a longitudinal 
mixed methods study of healthy volunteers’ participation in phase I clinical trials (see 
Edelblute & Fisher, 2015).2 From May to December 2013, we enrolled healthy volunteers in 
this larger study while they were participating in clinical trials at seven phase I clinics across 
2The University of North Carolina at Chapel Hill Institutional Review Board reviewed and approved the research protocol. As part of 
enrolment, participants completed an in-depth semi-structured interview exploring their history of participation in phase I trials, their 
perceptions of the risks and benefits of these clinical trials, the factors influencing their decisions to participate in studies, their 
experiences with the study staff and other participants as well as their confinement to the study facilities and their routine health 
behaviours, including diet, exercise, as well as use of tobacco, alcohol, illicit drugs, over-the-counter medications, prescription drugs 
and contraception. The interview also included questions about participants’ employment history, household configuration and 
economic stability. Interviews lasted an average of 70 minutes and ranged in length from 21 to 164 minutes, with much of the 
variability resulting from the number of clinical trials in which participants had previously enrolled.
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the United States. Participants were enrolled so that our sample would be drawn evenly from 
clinics in the east, midwest and west of the country. This recruitment strategy enabled us to 
enrol a demographically diverse and representative sample of individuals who participate as 
healthy volunteers in clinical trials (Table 1). As is typical of phase I trial participants 
(Fisher & Kalbaugh, 2011), our sample is predominantly men (74 per cent) and racial and 
ethnic minorities (68 per cent), with 40 per cent self-identifying as black, 32 per cent as non-
Hispanic white, 21 per cent Hispanic, 7 per cent as more than one race, 5 per cent as Asian, 
Native Hawaiian or Pacific Islander and 1 per cent as Native American.3 Additionally, 
nearly 20 per cent of our sample included participants who were born outside of the United 
States. More than 60 per cent of participants in our sample were between the ages of 30 and 
49, and 22 per cent were between the ages of 18 and 29.4 Participants had a wide range of 
experience as healthy volunteers; approximately 20 per cent were participating in their first 
clinical trial, 30 per cent were enrolled in their second through fourth study, 25 per cent were 
enrolled in their fifth through tenth study and 25 per cent reported participating in more than 
12 studies and upward to 200 clinical trials.
We also collected demographic information about participants’ educational attainment, 
employment status and household income (Table 1). For many participants in our sample (50 
per cent), the highest degree they received was a high school diploma or equivalent (GED), 
with approximately 29 per cent reporting they had taken some college classes. A smaller 
subset of participants (7 per cent) never finished high school or received a GED, and 11 per 
cent received trade or vocational training, such as certification in heating and ventilation, 
home inspection and cosmetology. Of those participants (33 per cent) who had received 
college degrees, 12 per cent had associate’s degrees, 18 per cent had bachelor’s degrees and 
3 per cent had graduate degrees (which include master’s degrees in music and psychology). 
As might be expected, it was only a small segment of our participants who were employed 
full-time (17 per cent). Approximately, one quarter of our participants had part-time work, 
but somewhat more (27 per cent) reported being self-employed.5 Finally, nearly a third of 
our participants were not employed. Reports of household income varied based on the 
number of adults with whom participants resided as well as their calculation of the wages of 
non-intimate partners (such as parents or room-mates), but our sample was distributed with 
17 per cent at less than $10,000, 29 per cent between $10,000 and $25,000, 40 per cent 
between $25,000 and $50,000 and 14 per cent at greater than $50,000 per year.
Interviews were transcribed in full, all identifying information was removed to ensure confidentiality and then the files were uploaded 
to Dedoose qualitative software for coding and analysis. Coding was a multi-staged process that began with the development of a code 
structure based on open coding of several transcripts. New codes and sub-codes were added as new themes emerged from the data. 
Each transcript was coded by at least two members of the project team, and a detailed memo was written for each transcript to 
encapsulate the major themes of the interview, especially in regard to participants’ perceptions of risk, clinical trial decision-making, 
their travel for clinical trials and a categorization of the volunteer ‘type’. Through the process of writing memos and categorizing 
participants into types, the participant as ‘entrepreneur’ emerged from our data. We further developed the theme of entrepreneurialism 
by refining our codes and analysing the transcripts through this lens.
3Data about ethnicity was collected separately from race, so the numbers do not total to 178. Hispanic participants also identified as 
white, black and more than one race.
4Note that only six participants in our sample were between the ages of 18 and 21, indicating that very few healthy volunteers in phase 
I trials are traditional college students.
5Many participants reported having multiple businesses through which they drew income, and clinical trials were one such activity 
that made some participants see themselves as self-employed. We used participants’ self-reports for employment status, so we did not 
standardize how clinical trial participation would count as work.
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Precarity and identities as professional ‘healthy volunteers’
We start from the position that the ‘healthy volunteers’ who participate in phase I clinical 
trials are independent contractors who are indispensable to the organizations for which they 
work and the industry as a whole. Drug development as we know it could not happen 
without these individuals allowing their bodies to be used to test drug toxicity and side 
effects, generating data that are transformed into intellectual property for pharmaceutical 
companies and are used to make decisions about which products to pursue (Corrigan, 2002; 
Fisher, 2015a). In this sense, these workers are engaged in a deeply embodied form of 
‘immaterial labour’ (Gill & Pratt, 2008; Lazzarato, 1996) or ‘clinical labour’ (Cooper & 
Waldby, 2014), providing a service that results in valuable symbolic content. 
Notwithstanding the industry term ‘volunteer’, phase I participants are typically serial 
participants, many of whom adopt professional identities as participants and seek out drug 
studies as their primary source of income. In the sections that follow, we draw upon our 
qualitative data to review some of the motivations of these workers, how they perceive 
themselves in relation to precarious labour markets and the creative strategies they employ to 
maintain a competitive edge within the ‘study game’. As we will illustrate, when healthy 
volunteers mobilize entrepreneurial narratives, they are doing important identity work, 
asserting hopeful visions of future autonomy and success in the face of the current 
unforgiving structural forces buffeting them. For most, entrepreneurial visions are 
subordinated in practice, as they accept the role of professional participant and seek degrees 
of relative economic security.
A means to an end
The threat of dead-end minimum wage jobs, unemployment or homelessness motivates 
many of our interviewees to pursue participation in clinical trials. Most of them 
acknowledge the potential risks of exposure to experimental drugs but either come up with 
rationalizations for their relative personal safety (e.g. being healthy, young) or criteria for 
not participating in studies they view as posing the greatest risk, either because of the 
condition being targeted (e.g. mental illness, HIV) or the procedures involved (e.g. lumbar 
punctures, radiolabels). Still, economic insecurity compels these workers to seek out drug 
studies in spite of initial or ongoing fears about their safety. One interviewee explained:
You could die, and seeing those words in black and white [on the informed consent 
form] that you can die, that really, it really took me back, like I read it a few 
different times. It’s like, wow … So I mean I did have reservations, but I think there 
is I guess a level of desperation at first when, when somebody chooses that this is 
the way that, you know, that they need to make that next bit of money and that it’s 
worth it, and they don’t know what is going to happen to them health-wise. (F2411, 
biracial man, emphasis added)6
6Participant IDs used throughout this paper give some information about each person. The letter indicates if the person was 
randomized to the full-participation (‘F’) or control (‘C’) arm of our study (for more information about this part of our study 
design, see Edelblute & Fisher, 2015). The first number of their ID indicates the region of the country from which they were 
recruited: ‘1’ is East, ‘2’ is Midwest and ‘3’ is West. The second number indicates their clinical trial experience: ‘1’ is first-time 
participants, ‘2’ is second-time participants, ‘3’ is third- through fifth-time participants and ‘4’ is participants with six or more 
trials. The final two digits of the ID are simply consecutive numbers to create unique IDs for each participant. To operationalize 
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While many of our informants do communicate masculinist expressions of bravery, others 
connect this directly to economic insecurity: ‘I wouldn’t call them [serial participants] risk-
takers, I’d just call them people with nothing to lose’ (F2402, black man).
Sometimes any sort of job is difficult to come by, particularly for individuals who are 
considered by employers to be risky investments. Thus, a number of our interviewees 
claimed that they did not have any viable alternatives because of being older, lacking college 
degrees, being overqualified or having a criminal record. The anxiety from being in such a 
situation can generate feelings of gratitude for phase I work: ‘These studies have been like a 
godsend [for me] because I mean, in today’s world, you know, you’re 50 years of age and if 
you need money and what do you do?’ (C2401, white man). For individuals who are 
disqualified from many jobs because they were previously convicted of felony crimes, the 
options may appear to be black-and-white choices between exploitative or dangerous labour 
or illegal activities, which would most likely lead to further incarceration:
[My friend] can’t really work, or he can, but he figured he would make more 
money doing these [studies] than he would working [at a fast food restaurant] on 
the account that he’s a felon, which they have a lot of people that do these studies 
are felons…I believe that most people would rather make money than go back to 
jail. (F2402, black man)
Some of our informants admit that they are hanging on ‘by the skin of their teeth’, staying in 
motels and living from day to day, just a step away from homelessness. Phase I studies can 
be a life-line for such people, especially if they have been denied employment everywhere 
else:
Ever since December, as soon as this year started, I’ve been unemployed. I’ve been 
getting interviews here and there. I’ve been non-stop filling out applications, 
whether it’s McDonald’s, Foot Locker, anything. And nobody hires me. I don’t 
know if it’s because I have tattoos on my neck and my hands. I guess I’m 
overqualified when I put certain jobs, how much I got paid. You know, so it’s been 
rough. So I find myself here at this study just because it’s Mayday [a distress 
signal] for me. And that’s why I’m here. I haven’t been working all year, so that’s-
that’s why I’m here. (F1110, Hispanic man)
With some exceptions, instead of internalizing blame, our interviewees see that being in an 
economic recession compounds their insecurity and limits the options available to them. 
They also treat phase I participation as a means to an end, striving to convert this access to 
financial resources into something bigger and better:
My goal is to take the money that I do gain and invest it or save it to make an 
accomplishment. It’s not like I’m trying to make a career out of it, but it has helped 
financially. So like my goal particularly is that I’m saving money, putting money to 
the side – besides paying bills – to buy small investments that leads to bigger 
things. So it’s just a game plan. You gotta come in with a plan. (F2202, black man)
our system, the gentleman quoted here with the ID of F2411 is in the full-participation arm, was recruited from the Midwest, and 
has participated in at least six studies.
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The reasons given for needing an exit strategy include recognition of the unreliability of 
clinical trial participation, concern about long-term negative health effects and lost time in 
terms of what individuals feel comfortable claiming as job experience. Even though 
participants operate as independent contractors and pay taxes, such employment cannot 
approximate levels of security associated with Fordist organizational relationships: ‘If I’m, 
you know, doing studies, you know, I don’t have a company contributing to a 401(k), you 
know, on my behalf, things like that. Like I’m not, I’m not climbing the corporate ladder’ 
(F2411, biracial man). Furthermore, because of the stigma attached to participation in drug 
studies, many individuals do not tell their families or friends about their work, and they 
certainly would not put it on their resumés. Participating in clinical trials is viewed as 
liminal work, perfectly legal but also not quite a part of the formal economy, which makes it 
seem all the more important to leverage study participation for something else.
Entrepreneurial dreams and hustling
With plenty of time on their hands when confined for studies, the entrepreneurial aspirations 
of healthy volunteers multiply and spread. Our informants describe many different planned 
business ventures, ranging from promoting artists, to owning dollar stores or gas stations, to 
running clubs or bars, to purchasing and flipping foreclosed homes. These visions share 
underlying goals of being self-employed, especially being an owner or CEO not responsible 
to any other person, and, of course, being wealthy. As one participant who did not complete 
high school expounded:
I’m the CEO of the company, but just really trying to branch out and really make it 
big…I’m not using this money [from clinical trials] to set me up to buy some grams 
and a pound of this and that [illicit] drug and hustle it. I’m not using this money to, 
you know, go splurging on a girl and be broke and then be alone … I’ll be using 
that money to invest in my businesses. So I want to start my own management 
company, my own record label, independent record label. And then I want to use 
that money if I make it big or whatever, I eventually want to have my own security 
company, my own, I eventually want to have my own bar, my own club. That’s my 
dream. So I can be a club owner. That’s my personality. (F1110, Hispanic man)
This hustler identity is key to how many informants view themselves, as another boasts: ‘I’m 
a hustler. So you could put me in the middle of the Sahara Desert, if there’s three villages 
there, I’m going to make me some money’ (F1329, black man). A different interviewee 
echoed the theme of leveraging his street experience of hustling and selling drugs to succeed 
both in clinical trials and in business ventures: ‘I’m still a hustler, you know … I just took 
my same hustler mentality, and now I’m putting it towards something legal, you know? 
Which this [clinical trials participation] is a hustle too, you know?’ (F1123, white man). In 
this formulation, hustling is both a fungible skill and scarce resource that can be used to gain 
competitive advantage over others in formal or informal economies.
Healthy volunteers with entrepreneurial aspirations see the time they spend in studies as 
productive. It affords them quiet space in which to hone their business strategies and 
network with others. For instance, one man explained:
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When I do these studies, it just gives me a lot of time to really, to plan, you know, 
‘cause I’m here all the time. It’s like I might as well think about what I’m gonna 
do, how I’m gonna make money for myself … Like you see all of these papers, you 
know, all I really, all I do is write things down … I gotta list a lot of stuff here, and 
most of it is like, it has to do with some health, it has to with some houses, it has to 
do with some loans, it has to do, it has to do with a lot of stuff and what I wanna 
accomplish when I get out of here and a lot of people I gotta call. (F1423, black 
man)
Because there is a captive audience of potential customers or business partners, these self-
described hustlers take advantage of that as well:
I’ll be profiting a lot more money next year with my business, so that’s what I’m 
looking forward to. Right now I’m in the process of building clientele, and like, like 
I said, when I be doing studies, and also anywhere I go and meet people, I give 
them my business card. I give them my business cards to everybody I meet, you 
need your house cleaned? You need a home makeover or whatever, events planned 
or whatever like that. (F3460, black man)
In our visits to clinics to recruit participants for our study, we also witnessed this 
combination of hustling, networking and entrepreneurialism manifest in individuals selling 
gift baskets, roses, bootlegged DVDs and other merchandise to each other. While not 
everyone harbours entrepreneurial dreams, this was clearly a dominant identity construct 
among our informants.
Because of the financial resources made possible through phase I clinical trials, many 
participants view eventual success with their entrepreneurial plans as guaranteed and – in 
neoliberal Darwinian fashion – blame those who do not succeed for their own failure, 
whether because of being stupid or lacking commitment. One man who has plans to make a 
fortune by buying houses, renovating them and renting them out, said:
If a person is not wealthy from doing studies within like a 10-year frame, then they 
[are] just a fuck up, blow off money, show off, buy stuff they probably don’t need. 
You know, 10-year frame, if you’re not wealthy, then you’re a fool, a real fool … 
Like, I got big ideas. I plan on making inventions and getting patents, and stuff like 
that. And I got money to do the stuff like that now. You get what I’m saying? 
(F2302, black man)
There is a perception that if people fail, that it is somehow because they lacked the requisite 
discipline to succeed. Another participant who is also involved in real estate articulated this 
position in a gentler fashion:
I’ve seen people that, that have blown through money and it’s like, wow, I mean 
you have a great opportunity to get ahead and really do something. And I don’t like 
to be judgmental so I don’t say anything, but just in my, thinking to myself, like 
man, you know, so I don’t want to be one of those people. I want to make 
something out of it. (F2404, black man)
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Based on our other interviews, it does seem accurate that there is a tendency among 
participants to use their earnings to pay off bills or purchase big-ticket items like plasma 
televisions, not necessarily to invest in outside business ventures. Part of this is definitely 
structural because when participants are released from confinement and finally paid, the 
large lump sum enables momentary extravagance that would not otherwise be possible and 
which can be used to acquire symbolic capital within their communities (e.g. friends or 
family members who cannot afford such consumer goods). What is perhaps more 
interesting, though, is the way that entrepreneurial narratives serve to rationalize exposure to 
risk in clinical trials, nourish dreams of a better life, and reposition street skills in hustling as 
unique assets instead of liabilities. All the while, the narratives ascribe personal failing as the 
reason for people’s inability to become rich, or just make ends meets, in the current 
economy.
The job of study participation
Volunteers in phase I clinical trials might be drawn to the job initially out of a sense of 
desperation or limited viable alternatives, and entrepreneurial narratives help compensate for 
the uneasiness individuals feel in this occupation. However, as they come to accept the 
identity of professional participant, these individuals approach participation in clinical trials 
as a competitive ‘job’ that requires a significant amount of uncompensated labour in order to 
secure the possibility of being chosen for studies.
The labour of trying to secure work begins with the drudgery of finding available studies, 
travelling great distances, often across state lines, to the clinics, successfully screening for 
studies and lining up and timing the next study after that one. In order to be successful with 
scheduling work, one must be diligent, patient and systematic:
It’s true that you-you can miss out on the really good studies if you’re not calling 
every day … I’d probably get in more studies, better studies, if I would, did spend 
that-that much time calling every day, but it’s tedious, all the calls and waiting on 
hold forever and going through a long, you know, description of the study and 
mostly it’s being on hold forever … So if you can deal with that, you know, several 
hours a day, you know you’re gonna get a lot better studies more often. (F2412, 
white man)
Participants also stress the need for developing relationships with clinic staff so that one is 
given insider information about future studies, especially well-paying ones. While some find 
this to be a tiresome process or unrealistic expectation given other life demands, others 
approach calling clinics as a challenge akin to seducing women:
You know when you’re confident, you’re confident all the way. It’s like going for a 
girl, female. If you’re half-stepping,7 she’s gonna sense it, they’re like animals, like 
if you half-stepping it, they’re gonna sense it: ‘Oh, this guy’s scared of me, he’s not 
getting my number, he’s a little wimp, you know, I like a confident man’, you know 
what I mean? So studies are like that, you have to go into ‘em with that, that 
mindset, like I’m gonna get in, you know. (F2406, biracial man)
7‘Half-step’, in this usage, means ‘to start something with no intention of finishing’ (Urban Dictionary, 2014).
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Such masculinist orientations fit well with the hustler identities of many participants, 
especially those who view their experience of drug side effects as a sign of bravery or 
strength. More than that, the narratives also discursively emasculate individuals who are 
unable to locate, screen and qualify for well-paying studies.
In order to maintain a tight schedule of studies, which is necessary for achieving a 
sustainable income, participants routinely violate the stipulation that they observe a 
minimum 30-day washout period between studies. The rationale behind this requirement is 
that experimental drugs, if present, can be purged from participants’ bodies before 
individuals are exposed to additional drugs. This is intended to maintain the integrity of the 
science and also protect participants from dangerous, unintended drug interactions. In 
practice, though, it is rare for professional participants to observe such washout periods 
voluntarily:
So it’s supposed to be 30-day washout period, but nobody does a 30-day washout 
period … You can always, you know, take supplements that will, you know, boost 
your hemoglobin and your iron back up to where it’s supposed to be. So otherwise, 
I mean a lot of people, if you do this for a living, waiting every 30 days, you’re not 
gonna make any money. So a lot of us, you know, jump from one study to another 
study within like a week or two weeks. (F2410, white immigrant woman)
Some of our informants even confess to being enrolled in multiple studies simultaneously, 
which is technically possible if they are in an ‘outpatient’ component of studies that require 
follow-up testing at scheduled intervals rather than sustained confinement. Because clinics 
maintain their own records of when individuals participated in studies last, healthy 
volunteers simply rotate among clinics and make certain that they allow 30 days to pass 
before returning to the same site. As a rule, volunteers also try to avoid studies that require 
follow-up visits after the confinement period because such visits can extend their 30-day 
wait period and can also introduce additional expenses, such as commuting to a distant 
location or feeling compelled to remain in a region, perhaps incurring motel and food 
expenses, as they wait for the scheduled follow-up tests.
Many other job-related expenses and risks are offloaded onto participants, making the 
mitigation of such things also part of the ongoing labour of this occupation. For instance, 
several participants told us about incurring unreimbursed medical expenses after manifesting 
frightening adverse effects while being dosed with experimental drugs in phase I clinics. 
One woman described such a situation where her blood pressure spiked to dangerous levels:
Yeah, even the nurses got scared. You know, they were like, ‘Oh my God’, ‘cause 
like I said, they even brought a crash cart, because I mean it was just I had a blood 
pressure of 172 and a heart rate of 144. Come on … So and from that, I got banned 
from a couple of places due to [the fact that] my ECG’s were abnormal [afterward] 
… Well, they told me to go see a cardiologist. They told me, and they told me I 
cannot participate in any studies in [that clinic] until I show ‘em that I went to a 
cardiologist.
Interviewer: Okay. Is that expensive?
Monahan and Fisher Page 11













Yeah, it was about $3,000.
Interviewer: Wow.
Yeah, my insurance only covers some of it. So then I brought the, the bill to them 
[the phase I clinic] and they refused paying it. (F2410, white immigrant woman)
Experiences like this, and other participants’ awareness of such situations, generate wariness 
of risky studies. One man described being ‘burned’ a few times by the long-term effects of 
studies:
I’ve been burned a couple of times. Like I did one, I did one [study] at [a clinic] 
where it raised your cholesterol … which I didn’t mind doing, but then I found out 
it-it kept your cholesterol up for a long time, so I, I wasn’t able to get into other 
studies for like several months afterwards, and I had to really work to get my 
cholesterol down. Then there was one that messed-messed with your white blood 
cell count. So there was a couple of years that my white blood cell count was really 
low, and I was getting declined from, rejected from studies because of that, and I 
could trace it back to the study that-that-that was a side effect. So my-my main 
concern is will the side effects prevent me from getting other studies, you know? 
(F2412, white man)
What these stories reveal is that while participants may be concerned about health risks 
caused by study drugs, some of these concerns are, in fact, motivated by a fear of perceived 
risk to future employability.
Voluntarily taking on additional expenses and making personal sacrifices can be viewed as 
necessary ‘investments’ in order to succeed in this occupation. For example, because of 
restrictions on women ‘of childbearing potential’ participating in phase I studies, out of fear 
of (legal liability for) potential birth defects, pharmaceutical company sponsors sometimes 
require proof of surgical sterilization before women can screen for studies. One woman 
describes her decision to become sterilized for this work:
This is kinda embarrassing to admit. Nobody knows this, not one person in my life, 
not my family or friends, but I got my, I got a procedure called Essure, E-s-s-u-r-e. 
There were so many good paying studies coming up for women who were 
surgically sterile or postmenopausal and I was never qualifying for them. Even 
though I was completely abstinent, they [the clinics] don’t believe you, you know. 
So I had health insurance and they paid for this procedure. It was just an inpatient 
visit basically. It was a little more painful than they thought, [than] they said it was 
going to be, but anyway. So then I became a surgically sterile category and I could 
get into these, quite a few of these better paying studies. Like the $6,000 one was 
for women who are surgically sterile. So even though I had, I had no chance of 
getting pregnant, I did that [voice drops to a whisper] just to qualify myself for 
better studies. (F2421, white woman)
In a less extreme vein, other participants describe compromising their moral principles, such 
as opposition to genetic sampling, out of fear of being excluded from studies if they object:
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They say it [giving a genetic sample as part of the study] doesn’t affect whether 
you’ll be accepted into the study, but I don’t trust that. I bet it does affect it, so I, so 
due to that pressure, I go ahead and accept the genetic testing anyway, even though 
I’d rather not. (F2412, white man)
A sense of precarity, therefore, motivates not only participation in what is perceived to be a 
risky and stigmatized line of work; it also compels financial and personal sacrifice for the 
possibility of being competitive at it.8
Tricks of the trade
Participants in phase I trials engage in a dizzying array of creative practices to make a living 
out of studies. Maintaining healthy bodies, through lifestyle choices and innovative 
experimentation with diet and supplements, is one way that participants prepare themselves 
for employability. Thus, with much variation, they work in between studies to maintain their 
competitive edge by dieting, exercising, not smoking, not drinking alcohol or caffeine, 
avoiding recreational and over-the-counter drugs, getting sufficient sleep, drinking lots of 
water and so on. As one participant explained, the extreme scrutiny and legibility of one’s 
body obliges such an approach: ‘They [clinic staff] will look for your blood pressure, your 
whatever things, BMI [body mass index], your heart rate, your everything, your urine, your 
blood samples, everything. So you have to be healthy [at] any time’ (C2405, Asian 
immigrant man).
Consequently, participants develop sophisticated regimens for staying healthy and keeping 
their lab results within acceptable ranges. They work out regularly between studies, but taper 
off right before screening so that their liver enzymes will not be elevated, which would lead 
to them failing the screening. They eat blueberries, arugula, spinach, kale, salmon, yogurt, 
raw garlic, and other expensive health foods to maintain measurable health. They develop 
nutritional and medical expertise, observing their lab results and adjusting behaviour 
accordingly. Some take milk thistle, ginseng and flaxseed to clean out their systems and get 
their liver enzymes back to acceptable ranges; most take multivitamins and iron 
supplements, sometimes even sneaking them into facilities, in order to boost the depleted 
hemoglobin and iron in their blood.
They are also not opposed to experimenting. One participant, for instance, recommended 
detoxification through the consumption of charcoal:
Charcoal has the ability to remove toxins from your body, has the ability to remove 
800 times the weight of whatever amount of charcoal you induce … You can get 
your fireplace all ready and go in and then maybe burn some good oak and-and out 
of that, what’s left, you know the-the-the carbon itself? Take it out and grind it, you 
know a good clean piece of oak? Or if you can’t get it like that, then you can go to 
the health food store and buy charcoal. It’s called activated-activated charcoal. It 
comes in capsules, and then if you do about two or three teaspoons in a cup of 
8Our informants describe numerous personal sacrifices endured for this work and the confinement required by it: missing their 
children’s birthdays and graduations, feeling unable to date or have long-term relationships, losing friends because of not having time 
to go out with them – and many more.
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water, stir it, you know, and then drink it like two or three times. That’ll scrub you. 
It’ll take out whatever, you know, and you do it two or three times say after a study, 
say you do it two, three days in a row, you’re pretty much cleaning out a lot of what 
was left in there … It’ll tone you back up and you’re ready [for your next study]. 
(F3431, white man)
Similarly, another participant consumes gallons of water with lemon juice to detox:
I have an 11-day washout period [before I start my next study]: a lot of lemon water 
… Lemon water dilutes and cleans our your body toxins and everything … That’s 
the best way to clean out your system as far as like, as far as the [investigational] 
drug, as far as this drug, it’s a lot of gallons of lemon water. (F2402, black man)
The point of such practices is to speed up the body’s washout period (if not the clinics’), 
adjusting it to the schedule of healthy volunteers so that they can get back to work more 
quickly.
Because the screening process is the point at which most participants are either included or 
excluded from a study, this becomes the moment subject to the most manipulation by 
prospective volunteers. First, as we have already mentioned, many participants do not 
observe stipulated washout periods, so they mislead screening staff about when they last 
participated in studies. Second, participants will screen for multiple studies scheduled for the 
same dates, and if they are selected for more than one study, they will choose the one that 
best fits their criteria (e.g. best pay, fewest follow-up visits, safest, most convenient). In 
effect, they regularly hedge their bets. Third, if studies require that individuals live in the 
area, which is something that could give clinics confidence in participants returning for 
follow-up visits, some admit to listing addresses of acquaintances or foreclosed homes rather 
than their real places of residence. Fourth, if possible, they will alter their bodies to increase 
their competitiveness for the requirements of specific studies. For example, if they are told 
what the acceptable body mass index (BMI) range is for a study, they can either gain or lose 
weight in advance to meet that criterion. This can extend to other measurements beyond 
weight too, as one interviewee explained:
It’s funny how I did the cholesterol study because I don’t have high cholesterol, just 
saying. But it didn’t have to be high cholesterol, it had to be slightly elevated. So in 
order to get in that study, I know this is going to seem funny or weird, I ate a lot of 
eggs and fish over the course of two weeks to get my cholesterol slightly elevated 
just enough to get in. And I did. Yeah. (F2402, black man)
Fifth, participants can fool so-called objective measures, such as BMI, by doing things like 
adding padding in their socks to add an inch to their height, thereby lowering their measured 
BMI so that they can qualify for studies. Sixth, screening can be rigged in one’s favour by 
having one’s friends sign up for screening appointments, so that the quota of potential 
volunteers is filled, but then those friends intentionally neglect to show up. These are just a 
few of the many tricks that healthy volunteers use to game screening processes.
Getting into studies is not sufficient, though, because individuals must also strive to 
maximize their financial gain. Once enrolled in a study and confined to a clinic, participants 
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can also manoeuvre to be dismissed early if they know it will not cut into their funding. One 
interviewee explains the nuances of this from his experience with a study measuring blood 
pressure:
That was a memorable study because they served us this salsa that had like 1,280 
milligrams of sodium, so people knowing that [for this particular study] once their 
blood pressure goes up, they’re going to be able to go home, you have people that 
are trying to eat, you know, all this sodium, and they’re putting salt in water and 
drinking it so that their blood pressure will go up so they can get sent home with 
the full money. And then that-that’s pretty funny, right? Then you got the one guy 
that doesn’t have money to leave once the study’s over, so he doesn’t want to get 
sent home. So he doesn’t eat the salsa. So he doesn’t have any salt on his food 
because he doesn’t want to get sent home early ‘cause he can’t afford it. He’s not 
gonna have any money until the study, until the study gets out and he gets his direct 
deposit. (F2411, biracial man)
Clearly, gaming studies for one’s personal benefit is highly contingent on one’s current 
financial situation: where some view getting out early as freeing up time for more work, 
others see it as introducing additional hardship because they do not have the resources to 
stay at a motel or travel home. These examples are indicative of the agency and creative 
responses of participants as they attempt to succeed in this competitive labour market.
Conclusion
This paper has explored the identities and practices of individuals participating as healthy 
volunteers in phase I clinical trials, with specific attention to their mobilization of creative or 
entrepreneurial responses to precarious labour conditions. Rather than passive ‘volunteers’, 
we see instead workers who are actively trying to shape the opportunities they have for 
income in an unpredictable market. Such healthy volunteers are essential contract workers 
for the clinical trials industry and the many ancillary organizations that conduct 
pharmaceutical studies, yet many of these workers participate out of a sense of profound 
financial need. An entrepreneurial ethos allows them to view personal sacrifice and exposure 
to potentially dangerous drugs as smart investments, as stepping-stones to more financially 
stable and fulfilling lives. Creativity becomes both a means of competing with others on the 
margins, for inclusion in studies, and an expression of agency that affords a sense of 
personal satisfaction. Especially interesting are the ways that individuals construct their 
identities as professional participants. They see clinical trials as a job for which they must 
diligently train in order to strategize for the possibility of employability. They import the 
identity of ‘hustler’ from the street environment and reposition it as positive, as connoting a 
set of valuable skills that give them an edge over others. For individuals who have little 
symbolic capital on which to draw, this move builds their sense of self-worth and offsets any 
shame associated with participating in stigmatized human experimentations.
Whereas insecure and casualized models of work have permeated across employment 
sectors (Gregg, 2011; Neilson & Rossiter, 2008; Ross, 2008), the adoption of creative or 
entrepreneurial identities by low-wage workers, like phase I participants, indicates a cultural 
shift that performs on several levels. Various acts of non-compliance and ingenious 
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scheming may generate pleasure for these workers, but these acts are also necessary for them 
to subsist. In this sense, we can situate the creative manoeuvres of healthy volunteers in a 
deeper history of tactical responses by the poor to survive in hostile circumstances (Gilliom, 
2001; Scott, 1985; Wacquant, 1998). At the same time, these creative responses do nothing 
to challenge the structural conditions of precarity, and they may unwittingly solidify these 
conditions by normalizing extractive, and at times dehumanizing, labour relations that 
offload expenses and risks to employees.
Because logics of self-exploitation undergird much contemporary creative work and 
entrepreneurialism, it is important to critique these constructs and their effects. Our findings 
build upon the valuable scholarship theorizing precarity in other sectors. Some have 
analysed those working in creative industries, including television programming, publishing, 
graphic design, advertising, music and software coding (Neff, 2012; de Peuter, 2011; 
Terranova, 2004; Umney & Kretsos, 2015). Others have noted how many organizations have 
learned from technology companies to cultivate ‘fun’ work-places that encourage total 
worker investment and team participation, which serve as soft mechanisms of social control 
to normalize exploitative and ultimately insecure work conditions (Fleming, 2007; Mumby, 
2013; Ross, 2003). Still others have shown how new media technologies facilitate the 
colonization of personal spaces and identities by professional ones, while individuals 
shoulder the burden and cost of constant re-skilling to maintain the possibility of future 
employability (Gill, 2007; Gregg, 2011).
In the context of phase I trials, our interviewees mobilize creative responses to manage their 
experiences of a generalized economic precarity as well as the insecure labour of clinical 
trials. As in sectors with more cultural capital, an entrepreneurial ethos becomes an 
important mechanism for healthy volunteers to assert agency and generate discourses of 
value and meaning for the work they do. Against this backdrop, however, entrepreneurial 
dreams may act like a will-o’-the-wisp, luring participants into long-term exposure to 
potentially dangerous experimental drugs for the elusive promise of eventually becoming 
rich doing what they love.
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Table 1





  18–21 6 3.4
  22–29 34 19.1
  30–39 58 32.6
  40–49 54 30.3
  50+ 26 14.6
Race/Ethnicity
  Non-Hispanic white 57 32.0
  Black 72 40.4
  American Indian 2 1.1
  Asian 6 3.4
  Native Hawaiian or other Pacific Islander 2 1.1
  More than one race 13 7.3
  Hispanic 38 21.3
  Foreign born 35 19.7
Educational Attainment
  Less than high school 12 6.7
  High school or GED 37 20.8
  Some college 52 29.2
  Trade/Technical/Vocational training 19 10.7
  Associate’s degree 21 11.8
  Bachelor’s degree 32 18.0
  Graduate degree 5 2.8
Employment Status
  Full-time 30 16.9
  Part-time 40 22.5
  Self-employed 48 27.0
  Not employed 58 32.6
  Retired 2 1.1
Household Income
  Less than $10,000 30 16.9
  $10,000 to $24,999 52 29.2
  $25,000 to $49,999 70 39.3
  $50,000 to $74,999 14 7.9
  $75,000 to $99,999 7 3.9
  $100,000 or more 4 2.2
Clinical Trial Experience
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N %
  1 study 38 21.3
  2–4 studies 49 27.5
  5–10 studies 45 25.3
  11–200 studies 46 25.8
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